Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The inspection concluded with NIL observations
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
Rivaroxaban is used to treat venous thromboembolism
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Marksans Pharma gets USFDA nod for acid reflux drug
Subscribe To Our Newsletter & Stay Updated